Gan & Lee Pharmaceuticals Expands Global Reach with New Exclusive Licensing Agreement
Gan & Lee Pharmaceuticals, a prominent biopharmaceutical leader in China, has announced the signing of an exclusive licensing agreement on April 8, 2026. This strategic move underscores the company’s commitment to expanding its international footprint and enhancing the availability of its specialized medical solutions on a global scale.
Who is Gan & Lee Pharmaceuticals?
Founded in 1998 and headquartered in Beijing, Gan & Lee Pharmaceuticals (SSE: 603087) specializes in the research, development, and commercialization of insulin analogs and medical devices. The company holds the distinction of developing the first domestic insulin analog in China.
Operating from an industrial park of approximately 200,000 square meters, the company employs more than 5,500 people globally. Their business model integrates the production of active pharmaceutical ingredients (APIs) with the manufacture of finished injections and delivery devices.
Comprehensive Product Portfolio
Gan & Lee provides a diverse range of insulin products designed to manage diabetes, including:
- Basalin: An insulin glargine injection.
- Prandilin: An insulin lispro injection, including the Prandilin 25 (insulin lispro mix 75/25).
- Rapilin: An insulin aspart injection, including Rapilin 30.
- Similin 30: A mixed protamine human insulin injection.
To support these therapies, the company also produces essential medical hardware, such as the GanleePen insulin injection device and GanleeFine insulin pen needles.
Strategic Growth and Global Partnerships
The recent licensing agreement announced on April 8, 2026, is part of a broader strategy to move beyond the Chinese market. Gan & Lee has previously established a commercialization and supply agreement with Sandoz to help expand its reach into developed markets.
Key Takeaways: Gan & Lee at a Glance
| Feature | Details |
|---|---|
| Founded | 1998 |
| Headquarters | Beijing, China |
| Stock Code | 603087.SS / 603087.SH |
| Core Focus | Insulin analogs and diabetes medical devices |
| Global Workforce | 5,500+ employees |
Looking Ahead
By securing exclusive licenses and partnering with international entities, Gan & Lee Pharmaceuticals is transitioning from a domestic leader to a global competitor. These initiatives aim to provide scientific solutions to patients worldwide, potentially increasing access to affordable and effective insulin therapies.
Frequently Asked Questions
What does Gan & Lee Pharmaceuticals produce?
The company produces various insulin analog injections, such as Basalin and Rapilin, as well as insulin delivery devices like the GanleePen.
Where is the company based?
Gan & Lee is headquartered in Beijing, People’s Republic of China.